Background: The aim of this study was to analyze the prevalence and incidence of adult-onset myasthenia gravis (MG) in the Belgrade population from 1979 to 2008. Methods: Data on the number of MG patients and their basic demographic and clinical characteristics were collected from hospital records (1979–1992) and the Belgrade MG Registry (1993–2008). Incidence and prevalence were standardized by the direct method (using the world standard population). A time-trend analysis of MG incidence was performed using a linear regression model. Results: During the study period 562 cases (316 women, 246 men) were registered. On December 31st, 2008, the standardized prevalence (according to the world standard population) was 188.3/1,000,000 (women: 237.8/1,000,000; men: 139.4/1,000,000). The average annual standardized incidence rate was 13.3/1,000,000 (women: 14.1/1,000,000; men: 12.2/1,000,000). The incidence rates tended to increase significantly in both sexes during the study period (y = 3.299 + 14.363x, p = 0.002). Age-specific incidence rates for women demonstrated a bimodal pattern, with the first peak in the 20- to 29-year age group and the second one in the ≥70-year group. For both genders, an increase in age-specific incidence rates was registered for all age groups, although this was significant (p = 0.001) only for an MG onset of ≥60 years of age. Conclusions: The study confirms an increase in the incidence of MG in the area of Belgrade during the study period, especially for those with MG onset after 60 years of age.

Keywords:
Myasthenia gravis, Incidence, Prevalence, Time trends
1.
Meriggioli MN, Sanders DB: Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009;8:475–490.
2.
Carr AS, Cardwell CR, McCarron PO, Mc Conville J: A systemic review of population-based epidemiological studies in myasthenia gravis. BMC Neurology 2010;10:46.
3.
Mc Grogan A, Sneddon S, de Vries CS: The incidence of myasthenia gravis: a systemic literature review. Neuroepidemiology 2010;34:171–183.
4.
Phillips LH: The epidemiology of myasthenia gravis. Ann NY Acad Sci 2003;998:407–412.
5.
Meyer A, Levy Y: Geoepidemiology of myasthenia gravis. Autoimmun Rev 2010;9:383–386.
6.
Chiang LM, Darras BT, Kang PB: Juvenile myasthenia gravis. Muscle Nerve 2009;39:423–431.
7.
Matsui N, Nakane S, Nakgawa Y, Kondo K, Mitsui T, Matsumoto T, Arisawa K, Kaji R: Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan. J Neurol Neurosurg Psychiatry 2009;80:1168–1171.
8.
Casetta I, Groppo E, DeGennaro R, Cesnik E, Piccolo L, Volpato S, Granieri E: Myasthenia gravis: a changing pattern of incidence. J Neurol 2010;257:2015–2019.
9.
Aragones JM, Bolibar I, Bonfill X, Bufil E, Mummany A, Alonso F, Illa I: Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003;60:1024–1026.
10.
Pakzad Z, Aziz T, Oger J: Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology 2011;76:1526–1528.
11.
Pallaver F, Riviera AP, Piffer S, Ricciardi R, Roni R, Orrico D, Bonifati DM: Change in myasthenia gravis epidemiology in Trento, Italy, after twenty years. Neuroepidemiology 2011;36:282–287.
12.
Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB: Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16–23.
13.
Lilienfeld DE, Stolley PD: Foundations of Epidemiology. New York, Oxford University Press, 1994.
14.
Annual statistical report for Belgrade (1979–2008). Municipal Institute of Statistics, Belgrade.
15.
Jensen OM, Parkin DM, Lennan R, Muir CS, Skeet RG: Cancer Registration: Principles and Methods. Lyon, International Agency on Research Cancer, 1991.
16.
Fleiss JL: Statistical Methods for Rates and Proportions. New York, Wiley, 1981.
17.
Lavrnic D, Jarebinski M, Rakocevic-Stojanovic V, Stevic Z, Lavrnic S, Pavlovic S, Trikic R, Tripkovic I, Neskovic V, Apostolski S: Epidemiological and clinical characteristics of myasthenia gravis in Belgrade, Yugoslavia (1983–1992). Acta Neurol Scand 1999;100:168–174.
18.
Robertson NP, Deans J, Compston DAS: Myasthenia gravis: a population-based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry 1998;65:492–496.
19.
Farrugia ME: A limited epidemiological study of seropositive myasthenia gravis in Tayside. Scott Med J 2002;47:132–135.
20.
Phillips LH, Torner JC, Anderson MS, Cox GM: The epidemiology of myasthenia gravis in central and western Virginia. Neurology 1992;42:1888–1893.
21.
Tatari-Calderone Z, Stojakovic M, Dewan R, Le Bouder G, Jankovic D, Vukmanovic S: Age-related accumulation of T cells with markers of relatively stronger autoreactivity leads to functional erosion of T cells. BMC Immunol 2012;13:8.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.